Anagrelide’s mechanism of action

Anagrelide (Anagrelide) is a drug used to treat essential thrombocythemia (essential thrombocythemia, ET). Its mechanism of action mainly involves the inhibition of platelet production and release to achieve the purpose of lowering platelet counts.

The mechanism of action of anagrelide mainly includes the following aspects:

1.Inhibition of phosphonucleotide cyclase (phosphodiesterase): Anagrelide inhibits the activity of phosphonucleotide cyclase, an enzyme that catalyzes the cyclization of phosphate nucleotides, thereby promoting the production and release of platelets. By inhibiting the activity of this enzyme, anagrelide reduces the degradation of adenosine diphosphate (cAMP) and increases the concentration of cAMP, thereby inhibiting the process of platelet production.

2.Inhibition of megakaryocyte maturation and differentiation: anagrelide acts on megakaryocytes in the bone marrow, preventing their maturation and differentiation. Megakaryocytes are platelet-producing cells that mature in the bone marrow and release platelets. Anagrelide inhibits platelet production by affecting the growth and differentiation of megakaryocytes.

3.Reducing platelet aggregation: Anagrelide also reduces platelet activity and aggregation by reducing platelet aggregation and adhesion. This helps reduce platelet aggregation in the blood, further lowering platelet counts and inhibiting the formation of blood clots.

Anagrelide is not yet on the market in China, so patients cannot purchase it domestically and need to purchase the drug through overseas channels. Anagrelide only has the original drug. Outside the mainland, there is the Hong Kong version of the original drug and the foreign Turkish original drug. The price is around 1280 yuan.